Average Insider

Where insiders trade, we follow

$GLSI
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Healthcare
Sector
Biotechnology
Industry
Snehal S. Patel
CEO
4
Employees
$24.98
Current Price
$345.39M
Market Cap
52W Low$7.78
Current$24.9865.3% above low, 34.7% below high
52W High$34.10

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00---
Sells00--
2 weeksBuys00---
Sells00--
1 monthBuys00---
Sells00--
2 monthsBuys00---
Sells00--
3 monthsBuys14$288,425.0011,900All Buys
Sells00--
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Jan 13, 2026
Patel Snehal
Director
Purchase1,800$29.83$53,694.00View Details
Jan 12, 2026
Patel Snehal
Director
Purchase2,900$27.54$79,866.00View Details
Dec 31, 2025
Patel Snehal
Director
Purchase4,300$21.36$91,848.00View Details
Dec 30, 2025
Patel Snehal
Director
Purchase2,900$21.73$63,017.00View Details
8 more transactions available โ€” create a free account to see 12 months of history

Upcoming Earnings

Scheduled earnings reports
Apr 21, 2026
EPS
Estimated-$0.32
ActualN/A
Revenue
EstimatedN/A
ActualN/A

Past Earnings

Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.
Version: v26.3.23